MetaCap

Canton Strategic (CNTN) vs Foghorn Therapeutics (FHTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Canton Strategic (CNTN) has outperformed Foghorn Therapeutics (FHTX) over the past year, losing 50.6% versus a loss of 62.8%. Foghorn Therapeutics is the larger company by market cap ($103.1 million vs $98.8 million), about 1.0 times the size. On valuation, Foghorn Therapeutics trades at a lower trailing P/E (19.1x vs 20.2x for Canton Strategic).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CNTN-50.61%FHTX-62.77%
+133%+30%-72%
Nov 21, 20251 yearNov 20, 2026
CNTN-99.89%FHTX-90.23%
+49%-29%-107%
Jan 10, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CNTN versus FHTX key metrics
MetricCNTNFHTX
Share price$1.21$1.72
Market cap$98.78M$103.14M
1-day change-1.63%-3.37%
YTD return-60.07%-68.15%
1-year return-50.61%-62.77%
5-year return—-87.36%
P/E ratio (TTM)20.1719.11
EPS (TTM)$0.06$0.09
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$30.91M
Revenue growth (YoY)—+36.75%
Net income (latest FY)$-35.92M$-74.28M
Operating margin—-279.49%
Net margin—-240.33%
52-week high$5.83$7.61
52-week low$1.19$1.66
Distance from 52-week high-79.25%-77.40%
Analyst consensus—buy
Avg. price target upside—+142.44%
Average volume763.63K843.73K
Shares outstanding81.64M59.96M
Employees12106
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CNTN has outperformed FHTX by 12.2 percentage points over the past year.

About Canton Strategic

CNTN stock →

Canton Strategic Holdings, Inc. focuses on advancing institutional blockchain adoption and digitizing financial markets in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

About Foghorn Therapeutics

FHTX stock →

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.

Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees

CNTN vs FHTX FAQ

Which is bigger, Canton Strategic or Foghorn Therapeutics?

Foghorn Therapeutics (FHTX) is larger, with a market capitalization of $103.14M compared with $98.78M for Canton Strategic (CNTN).

Which stock has performed better over the past year, CNTN or FHTX?

CNTN returned -50.61% over the past 12 months, compared with -62.77% for FHTX (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, CNTN or FHTX?

FHTX has the lower trailing P/E at 19.1, versus 20.2 for CNTN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are Canton Strategic and Foghorn Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons